Every story we've covered involving series-e.
Enveda, a biotech that uses AI to find drug candidates from plants and microbes, raised $311 million in a Series E at a $2 billion valuation. The funding round was led by Catalio Capital Management with participation from Iconiq and others, and the company currently has multiple AI-discovered drugs in human testing, including therapies for severe skin conditions and for maintaining weight loss after stopping GLP-1s.
No stories here yet.